drugset / Trial / NCT00924664

Long Term Safety Study of Tanezumab in Chronic Low Back Pain

NCT00924664

Phase 2 Terminated 849 enrolled Pfizer
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to investigate the safety and efficacy of tanezumab for chronic low back pain. Patients who were randomized and treated with study medication in a previous chronic low back pain "parent" study will be eligible to enroll in this safety extension study at the Preferred Rollover Time Point visit or at the Early Termination visit of the parent study upon discontinuation due to lack of efficacy.

Timeline

Start
2009-08-20
Primary completion
2010-11-30
Completion
2011-06-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Tanezumab Monoclonal antibody 10 mg Intravenous
Subject Tanezumab Monoclonal antibody 20 mg Intravenous

Indications

No indication recorded.